Industry Newsbiopharmapfizeroncologyearnings
Pfizer Presents Cautiously Bullish Investment Case
4.1
On March 15, 2026, the article summarizes a bullish thesis on Pfizer Inc., noting shares at $26.81 as of March 9 and P/E metrics of 19.89 trailing and 9.14 forward. It highlights fiscal 2025 operational resilience—non-COVID growth of 6%, adjusted EPS $3.22, Abrysvo +136% and oncology biosimilars +76%—but flags $4.4 billion impairments and 2026 guidance.
Key Points
- 1Reports Pfizer's fiscal 2025 non-COVID operational growth of 6% and adjusted EPS rising 4%.
- 2Highlights Abrysvo up 136% and oncology biosimilars up 76%, boosting long-term revenue visibility.
- 3Suggests income investors may favor PFE for yield and pipeline-driven stability, but execution matters.
Scoring Rationale
Provides actionable earnings and pipeline metrics; limited novelty and reliance on secondary analysis constrain industry-wide impact.
Sources
Public references used for this report.
Practice with real Health & Insurance data
90 SQL & Python problems · 15 industry datasets
Used by DS/ML engineers at top companies
250 free problems · No credit card
See all Health & Insurance problems
